Novel hormonal agents in men with metastatic castration resistant prostate cancer and reduced performance status: Experiences of a specialized single center

Abstract Objectives Attaining castration resistance in metastatic prostate cancer (mCRPC) represents a pivotal juncture in the progression of the patient's illness and treatment regimen. Within this therapeutic context, novel hormonal agents (NHA) constitute a fundamental component of pharmacol...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas Büttner, Philipp Lossin, Stefan Latz, Carolin Jacobs, Philipp Krausewitz, Stefan Hauser
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Aging Medicine
Subjects:
Online Access:https://doi.org/10.1002/agm2.12372
Tags: Add Tag
No Tags, Be the first to tag this record!